Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of Hemay007 in healthy volunteers
NCT02603185Phase 1Unknown
- Sponsor
- Tianjin Hemay Biotech
- Start
- Jan 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammatory bowel disease (IBD) comparing Hemay007 with Placebo (2 arms). Primary endpoint: Adverse events assessments. Status: unknown.
02
Drugs
hemay007
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02603185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603185.